Ecuador Resolucion ARCSA-DE-026-2016-YMIH: Amendments and Repeal Timeline

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

The current core regulation, Resolucion ARCSA-DE-026-2016-YMIH (published in Registro Oficial Suplemento 921 on 2017-01-12), will be expressly repealed on 2027-01-28. Over ten years it was amended 5 times (004-2017-CFMR, 033-2017-FMRH, 030-2018-JCGO, 2023-001-VSVZ and 2023-033-AKRG), producing an application landscape of one principal regulation plus multiple amendments.

2. Legal basis

RegulationReference numberPublication dateArticles / nature
Current core regulationResolucion ARCSA-DE-026-2016-YMIH, Registro Oficial Suplemento 9212017-01-12Principal regulation (to be repealed)
Amendment oneResolucion ARCSA-DE-004-2017-CFMR, Registro Oficial 9642017-03-16Amendment
Amendment twoResolucion ARCSA-DE-033-2017-FMRH, Registro Oficial 1562018-01-09Amendment
Amendment threeResolucion ARCSA-DE-030-2018-JCGO, Registro Oficial 4162019-01-29Amendment
Amendment fourResolucion ARCSA-DE-2023-001-VSVZ, Registro Oficial 2522023-02-16Amendment
Amendment fiveResolucion ARCSA-DE-2023-033-AKRG, Registro Oficial 4702024-01-04Amendment
New regulation (replacing instrument)Resolucion ARCSA-DE-2026-003-DASPSigned 2026-04-28Repealing provisions, items one and two

Cross-check note: ARCSA-DE-030-2018-JCGO was published on 2019-01-29 (Registro Oficial No. 416), not in 2018 as stated in some Chinese-language materials. The date is taken from the official listing in item one of the repealing provisions of the new regulation.

3. Expert insights

Insight one: the repeal is by express enumeration, not by blanket repeal. Item one of the repealing provisions lists the repealed resolutions one by one with their names, official gazette issues and publication dates, and item two separately repeals 2023-033-AKRG, except for its amending provisions. The benefit is a clear applicability map; the price is that the status of any companion instrument not listed must be judged individually.

Insight two: 030-2018-JCGO carries the current simplified registration pathway, and it will be repealed on 2027-01-28. That amendment introduced the simplified channel recognizing registrations from specific countries, which is replaced by the IMDRF recognition channel in Articles 31 to 33 of the new regulation. The difference in recognition standards between the old and new simplified channels is the core of this change: the old pathway was judged by specific countries, while the new pathway uses the standard of highly regulated agencies plus IMDRF membership, and its scope extends to all classes from I to IV.

Insight three: 2023-005-AKRG is not on the repeal list; on the contrary it is amended and expanded. Under item SEPTIMA of the amending provisions of the new regulation, in the table of Article 4 of ARCSA-DE-2023-005-AKRG, a new entry NDM017 is added after NDM016, covering submission of the final label after the registration certificate is granted, and submission on updates affecting an already approved final label. This shows the notification (notificacion) channel remains valid and is expanded under the new framework, and it is a companion channel that manufacturers in the Chinese mainland must track closely.

Insight four: the phrase except for its amending provisions in item two is a technical preservation. Resolution 2023-033-AKRG is repealed, but the amendments it previously made to other instruments remain in force. This is a reminder that, when applying the new regulation, the historical effects of past amendments on surviving instruments must be traced.

Insight five: the density of amendments reflects a fast-evolving system. Two amendments in 2017, one in 2019, one in 2023, one in 2024, and then wholesale replacement in 2026. A tracking mechanism cannot be a one-off exercise.

4. Practical recommendations

  1. Build a repeal ledger: mark each repealed resolution and the corresponding article in the new regulation that carries its institutional function.
  2. Compare the recognition standards of the old and new simplified channels in detail and re-evaluate the pathway choice for each product.
  3. Put the notification system of 2023-005-AKRG on the compliance calendar, especially the NDM017 final label obligation.
  4. Retain submission receipts for applications filed before 2027-01-28 to support a claim of transition-period applicability.
  5. Trace the historical effects of past amendments on surviving companion instruments, avoiding reliance on provisions that are no longer valid.

5. Verification checklist

  • □ Publication dates and gazette issues of the current core regulation and its 5 amendments have been confirmed
  • □ An old-versus-new mapping table has been built, item by item by institutional function
  • □ The pathway choice for each product (standard or simplified) has been re-evaluated
  • □ The NDM017 final label obligation has been placed on the compliance calendar
  • □ Submission receipts for applications filed before 2027-01-28 have been retained
  • □ The validity of every cited provision during the transition period has been confirmed

Regulatory information verified as of October 29, 2026

GRZAN core service lines

  1. Global registration access: EU CE (MDR/IVDR), US FDA (510(k)/De Novo/PMA), UK UKCA, Australia TGA, Canada Health Canada, Brazil ANVISA and Russia RZN, together with pre-market registration pathway planning and submission execution across Latin America, Southeast Asia and the Middle East.
  2. Authorized representative services: EU EC REP, UK RP, Swiss CH REP, Australian sponsor and US Agent holding and representation services, with support for neutral license-holder structures.
  3. Quality system compliance: ISO 13485 establishment and maintenance, MDSAP audit preparation, GMP conformity coaching, and technical documentation (TD) drafting and remediation.
  4. Clinical and evaluation support: clinical evaluation plans (CEP) and reports (CER), equivalence argumentation, PMCF planning and execution, and IVD performance evaluation.
  5. Post-market compliance: vigilance and adverse event reporting, FSCA and recall execution, registration change and renewal management, and maintenance of national regulatory databases.

Why manufacturers choose GRZAN

  • Local regulatory teams: target-market work is performed by locally licensed regulatory professionals, and submission dossiers are written directly in the local official language without secondary translation.
  • Neutral license-holder structures: GRZAN offers holding arrangements that are not tied to any distribution channel, preventing registration certificates from being locked in by channel partners.
  • Regional leverage: one technical dossier can be reused across Andean Community and Mercosur member states, spreading regional compliance costs.
  • Full lifecycle support: from classification determination and pathway design through dossier preparation, license holding, customs clearance, post-market vigilance and renewal.

Contact

  • GRZAN provides registration support in Ecuador for manufacturers, importers and authorized representatives.
  • Email: info@grzanglobal.com
  • Service inquiries: Ecuador and Andean market registration plans, license-holder structure design, official fee and timeline estimation

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail